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Abstract: Different gastrointestinal disorders, including inflammatory bowel diseases (IBD), have 
been linked to alterations of the gut microbiota composition, namely dysbiosis. Fecal microbiota 
transplantation (FMT) is considered an encouraging therapeutic approach for ulcerative colitis 
patients, mostly as a consequence of normobiosis restoration. We recently showed that therapeutic 
effects of FMT during acute experimental colitis are linked to functional modulation of the mucosal 
immune system and of the gut microbiota composition. Here we analysed the effects of therapeutic 
FMT administration during chronic experimental colitis, a condition more similar to that of IBD 
patients, on immune-mediated mucosal inflammatory pathways. Mucus and feces from 
normobiotic donors were orally administered to mice with established chronic Dextran Sodium 
Sulphate (DSS)-induced colitis. Immunophenotypes and functions of infiltrating colonic immune 
cells were evaluated by cytofluorimetric analysis. Compositional differences in the intestinal 
microbiome were analyzed by 16S rRNA sequencing. Therapeutic FMT in mice undergoing chronic 
intestinal inflammation was capable to decrease colonic inflammation by modulating the expression 
of pro-inflammatory genes, antimicrobial peptides, and mucins. Innate and adaptive mucosal 
immune cells manifested a reduced pro-inflammatory profile in FMT-treated mice. Finally, 
restoration of a normobiotic core ecology contributed to the resolution of inflammation. Thus, FMT 
is capable of controlling chronic intestinal experimental colitis by inducing a concerted activation of 
anti-inflammatory immune pathways, mechanistically supporting the positive results of FMT 
treatment reported in ulcerative colitis patients. 
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1. Introduction 
The intestinal mucosa is a complex environment where the host and the gut microbiome 
establish a mutualistic relationship [1]. Maintenance of intestinal homeostasis relies on different 
mechanisms aimed at physically separating the commensal microbial ecology from the intestinal 
lamina propria, controlling colonization by pathogenic bacteria, and preserving the mucosal immune 
cell functions [1]. The intrinsic resilience of the system allows subtle alterations of this equilibrium 
[2], unless chronic inflammatory insults or underlying genetic alterations establish a stable diversion 
from the normobiotic microbiome composition, as it is reported in patients suffering from 
inflammatory bowel diseases (IBD, Crohn’s disease (CD), and Ulcerative colitis (UC)) [3,4]. 
IBD patients and their first-degree relatives manifest a reduced biodiversity in both mucus-
associated and fecal microbial communities, including bacteria, fungi, and viruses [3,5,6]. Expansion 
of pro-inflammatory bacteria, such as Enterobacteriaceae and Fusobacteriaceae, and depletion of phyla 
with anti-inflammatory capabilities, such as Firmicutes, are observed in IBD patients [7]. Intestinal 
dysbiosis in IBD patients seem to temporally precede intestinal inflammation, as it has been observed 
in the ileal mucosa of children with treatment-naïve IBD [3]. These observations are mechanistically 
supported by the capability of dysbiotic microbiota or single commensal bacterial species to induce 
intestinal inflammation when transferred in germ-free mice [8]. 
Consistently, the chronic maintenance of a dysbiotic microbiota seems to be linked to some of 
the genetic alterations reported in IBD patients, e.g., NOD genes encoding for proteins and receptors 
involved in bacterial sensing [9]. Moreover, the chronic damage of the intestinal epithelium observed 
in IBD patients is a key event favoring bacterial translocation into the lamina propria, thus promoting 
the recognition of antigens derived from the dysbiotic microflora by pathogenic T cells [10]. 
Altogether these events support the hypothesis that an altered luminal microbiota composition 
fuels the prolonged recruitment and activation of immune cell types into the intestinal mucosa of IBD 
patients, contributing to chronically maintaining intestinal inflammation [10]. 
Both innate and adaptive mucosal immune cells are involved in pathogenic activities during 
intestinal inflammation [11]. Conventional CD4+ T helper (Th) cells have been shown to play key role 
in coordinating intestinal inflammatory responses [12,13], although other mucosal T cell populations. 
including Type 1 [14] and Type 2 Natural Killer T (NKT) cells [15,16], contribute to sustain intestinal 
inflammation. Conversely, regulatory T cell populations, such as Treg [17] and Tr1 cells [18], 
participate in the control of Th17-mediated pathogenic responses in IBD patients. 
Therefore, besides the control of the disease, restoration of a normobiotic core intestinal ecology 
[14,19,20] is becoming a long-term therapeutic goal in various gastrointestinal disorders [21]. One 
widely explored option to manipulate and treat disorders associated with microbiota alterations is 
fecal microbiota transplantation (FMT), i.e., the infusion of a healthy donor feces in the intestine of 
an affected recipient. At present FMT is receiving positive consideration thanks to therapeutic 
efficacy against refractory and recurrent Clostridium difficile infections (CDI) [22,23], but promising 
evidence is also accumulating from ongoing randomized clinical trials (RCTs) involving mild-to-
moderate UC patients [24–26]. 
Nonetheless, at present it is only partially understood how FMT functionally modulates the 
intestinal immune system [27,28]. We have recently shown that therapeutic FMT administered 
during acute experimental intestinal inflammation directly modulates both innate and adaptive 
mucosal immune responses towards control of intestinal inflammation [19]. Specifically, we showed 
that FMT is not only capable of restoring normobiosis and metabolic functions associated with 
beneficial commensals, but it also simultaneously activates multiple anti-inflammatory mechanisms 
targeting mucosal immune cell types and effector pathways linked to the production of tolerogenic 
IL10 by mucosal innate and adaptive cell subsets. 
Here, we extended our analyses to a chronic setting of intestinal inflammation. Our goal is to 
understand if a similar regulatory axis involving microbial normobiosis restoration and immune 
system regulation occurs when FMT is administered to chronically inflamed recipients, thus 
shedding light on the beneficial mechanism of action of FMT in IBD patients. 
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2. Materials and Methods  
2.1. Mice 
8–10 weeks old C57BL/6 (Charles River, IT) and CXCR6EGFP/+ (B6.129P2-Cxcr6tm1Litt/J ; 
IMSR_JAX: 005693, on C57BL/6 background, JAX, USA) female mice were housed at the European 
Institute of Oncology (IEO) animal facility in Specific pathogen free (SPF) conditions. Experimental 
groups of mice receiving different FMT treatments were separated in distinct cages and randomly 
assigned to the different experimental groups. 
Animal procedures were approved by Italy’s Ministry of Health (Auth. 415/2017). 
2.1. Experimental Colitis Models 
For the induction of chronic intestinal colitis, mice were given 2% (w/v) dextran sodium sulphate 
(DSS, MW 40 kD; TdB Consultancy) in their drinking water for 3 cycles of 7 days of treatment, 
followed by 14 days of water recovery. Mice were not treated with analgesics. Mice were weighted 
twice a week to determine the weight curve. At the end of the treatment mice were sacrificed and 
colons were collected. Firstly, colons were measured to determine their length, then they were 
divided into portions for different analyses, i.e. fixed in 10% formalin for histology, or in 
paraformaldehyde, L-Lysine pH 7.4 and NaIO4 (PLP buffer) for immunofluorescence, or snap-frozen 
for RNA and protein extraction and for lamina propria mononuclear cells (LPMC) isolation. 
Experimental groups were composed by n = 8 untreated, n = 10 chronic DSS (cDSS)- treated, n = 
10 chronic DSS + Faecal Microbiota Transplantation (cDSS + FMT) treated mice in 2 independent 
experiments. 
2.3. Fecal Microbiota Transplantation (FMT) 
To perform FMT treatment, mucus (first day) and faeces (second, third and fourth days) 
preparations from untreated (normobiotic) donors were orally administered to colitic recipient mice. 
The first day mucus was scraped from colons of untreated mice, diluted in Phosphate Buffered saline 
(PBS) and dispensed to recipients at 1:1 ratio by oral gavage. Next (days two, three and four of FMT 
treatment), faeces were collected from colons of untreated mice, diluted in PBS (50 mg/mL) and orally 
dispensed to recipients (10 mg/mouse) five days after the beginning of each DSS cycle. 
2.4. Histological Analysis 
Colonic tissues were processed with a LEICA PELORIS processor and then embedded in 
paraffin. Inclusion of murine tissue samples was performed with a robotic system (SAKURA Tissue-
Tek) as previously described [29,30]. Hematoxylin and Eosin staining was performed as described in 
[29,30] and snapshots of tissue histology were taken using an Aperio CS2 microscope (scanning 
resolution 50,000 pixels per inch, 0.5 µm per pixel with 10× objective and 2.5 µm per pixel when 
scanning at 4×). Disease activity scoring was performed according to the evaluation of the criteria 
listed in Supplementary Table 1. 
2.5. Quantitative Reverse Transcription PCR (RT-qPCR) of Tissue mRNA 
Total RNA was isolated from murine colonic tissues by using TRIZOL and Quick-RNA 
MiniPrep (ZymoResearch) following the manufacturer’s specifications and the MetaHIT project 
guidelines. 1µg of total RNA was used to generate cDNAs by utilizing the reverse transcription kit 
(Promega). qPCR were performed to evaluate gene expression levels, normalized to the expression 
of the Rpl32 gene. The primer sequences are listed in Supplementary Table 2. 
2.6. Tissue ELISA of Murine IL-10 
Portions of colonic tissues were homogenized in 300 µL RIPA Buffer (Cell Signaling Technology) 
containing Phosphatase (Sigma) and Protease (Complete Ultra tablets, Roche) inhibitors, incubated 
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under slow rotation (4 °C for 30 min) and then centrifuged at 13,000 rpm (16.2 g) for 15 min at 4 °C. 
Quantification of the supernatants was performed using Bradford Assay (BioRad) and measured 
with NanoDrop. 6.25 µg of lysate were used to determine tissue mIL-10 using the ELISA assay 
(Purified anti-mouse IL-10 and Biotin anti-mouse IL-10, Biolegend) according to the manufacturer’s 
instructions. 
2.7. Murine Cell Isolation 
To isolate lamina propria mononuclear cells (LPMC), Peyer’s Patches were firstly removed and 
then colonic tissue was incubated with 5 mM EDTA at 37 °C for 30 min, followed by digestion with 
collagenase IV and DNase (37 °C for 1 h). Colonic lamina propria lymphocytes (LPL) were then 
separated with a Percoll gradient. 
In some experiments, cytokine secretion by isolated LPL was determined upon re-stimulation in 
vitro for 3 h with PMA/Ionomycin in the presence of Brefeldin A. 
2.8. Flow Cytometry Analysis 
For immunephenotyping, cells were incubated with combinations of directly conjugated 
antibodies (annotated in Supplementary Table 3). iNKT cells were identified either by CXCR6-EGFP 
expression or by mCD1d:PBS57 Tetramer (NIH Tetramer core facility) staining. 
To detect intracellular cytokines, restimulated cells were fixed and permeabilized with 
Cytofix/Cytoperm (BD) before the addition of antibodies. Samples were passed on a FACSCanto II 
flow cytometer (BD). Data were analysed using FlowJo software (BD) and nonviable cells were 
excluded by gating. 
2.9. Immunofluorescence 
Colonic samples were fixed overnight in paraformaldehyde, L-Lysine pH 7.4 and NaIO4 
(Periodate-Lysine-Paraformaldeyde (PLP) buffer, freshly prepared in house). Samples were washed, 
dehydrated in 20% sucrose (at least 4 h) and included in the optimal cutting temperature (OCT) cryo-
embedding medium (Sakura, Alpen aan den Rijin, The Netherlands). Sections (10µm-thick) were re-
hydrated with 0.1M Tris HCl pH 7.4 buffer, blocked with 0.3% triton X-100, Tris-HCl buffer 0.1M 
containing 2% FBS. Slides were incubated with the primary antibody (anti-ZO-1 FITC, 1:100) for 2 h. 
Nuclei were counterstained with 4’,6-diamidino-2-phenylindole (DAPI) (1:30,000 Roche 
Biochemicals, Monza, IT) and mounted with Vectashield (Vectorlabs, Burlingame, CA). 
2.10. Bacterial DNA Extraction and 16S rRNA Gene Sequencing 
Feces and mucus scraped from the colon were stored at −80 °C until the DNA was extracted with 
G NOME DNA isolation kit (MP Biomedicals) following the manufacturer’s instructions.  
The 16S rRNA gene amplicon libraries were performed with a two-step barcoding approach 
according to Borgo et al. [31]. Briefly, the 16S rRNA gene was initially amplified by interest-specific 
primers targeting V3 (5′-
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG-3′),  
V4 (5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG-3′) 
regions coupled with overhang adapters. The reaction was carried out in 25 µL volume containing 6 
ng/µL microbial DNA, 1 µM of each primer, and 2x KAPA HiFi HotStart ReadyMix (Roche, Italy).  
The following PCR program was used: initial denaturation at 95 °C for 3 min, followed by 25 
cycles consisting of denaturation (95 °C for 30 s), annealing (55 °C for 30 s) and extension (72 °C for 
30 s), and a final extension step at 72 °C for 5 min. PCR products were analyzed by 1% agarose gel 
electrophoresis for quantity and quality. Expected product size after the Amplicon PCR step is about 
550 bp. 
DNA samples resulting from the PCR step were amplified with dual-index primers using 
Nextera Xt Index Kit V2 Set A (Illumina, San Diego, CA). Each sample possessed specific barcode 
sequences at the 5′- and 3′-end of the PCR amplicon for sample identification in the pooled library. 
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Library concentration and exact product size were measured using the Agilent 2100 Bioanalyzer 
System (Agilent, Santa Clara, CA, USA). A 20 nM pooled library and a PhiX control v3 (20 nM) 
(Illumina, San Diego, CA) were mixed with 0.2 N fresh NaOH and hybridization buffer HT1 
(Illumina) to produce a final concentration at 10 pM each. The resulting library was mixed with the 
PhiX control v3 (5%, v/v) (Illumina) and injected on a Miseq Reagent Nano Kit V2 500 Cycles to obtain 
a paired-end 2 × 150 bp sequencing. Sequencing was performed at the IEO Genomic Unit. 
2.11. Statistical Analysis 
2.11.1. Data Analysis 
Statistical significance was calculated with unpaired two-tailed Mann-Whitney test (two-tailed) 
and expressed as mean ± SEM. Values of P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***) were considered 
as statistically significant. Outliers were detected with Grubb’s test. 
2.11.2. Microbiota Sequence Analysis 
The 250 bp 16S reads were processed through QIIME2 (version 2018.11) [32] as follows: (1) 
Following visualization of demultiplexed samples and the average quality across the reads, quality 
filtering, dereplicating, and chimera filtering were performed using the DADA2 [33] plugin within 
QIIME2, with the following parameters: –p-trunc-len-f 250, –p-trunc-len-r 242, –p-trim-left-f 0, –p-
trim-left-r 0, –p-trunc-q 2, and using consensus as the chimera filtering method; (2) a phylogenetic 
tree was generated for downstream core diversity analyses using Multiple Alignment using Fast 
Fourier Transform (MAFFT) [34] for multi-sequence alignment and IQ-TREE [35] ultrafast bootstrap 
for tree generation, with the following parameters: –p-perturb-nni-strength 0.2 and –p-stop-iter 200; 
(3) alpha and beta diversity core metrics were assessed using the qiime diversity command; (4) 
taxonomy classification was performed using the qiime feature-classifier classify-sklearn feature, 
using a Naïve Bayes classifier [36] trained on SILVA database (release 132, 99% operational 
Taxonimic Units (OTUs) full-length 16S rRNA sequences), available from the QIIME2 website 
(https://docs.qiime2.org/2018.11/data-resources/). Taxonomy count tables for phylum, family, and 
species were generated after taxonomy classification and exported for manipulation and plotting 
outside of QIIME2. 
The QIIME2 frequency table, taxonomy table, phylogenetic tree, and metadata were imported 
as “physeq” R objects (R Core Team, 2013) using the phyloseq package [37]. Principal coordinate 
analysis of unweighted UniFrac beta-diversity distance matrix exported from QIIME2 and alpha 
diversity measurements of physeq object were determined by microbiomeSeq, with alpha-diversity 
pairwise comparisons assessed by ANOVA. Beta-dispersion pairwise comparisons on unweighted 
UniFrac values was performed in R using betadisper in vegan [38]. Pairwise PERMANOVA of 
unweighted UniFrac values was performed separately using pairwise Adonis in R using the default 
Bonferonni p-value correction (https://github.com/pmartinezarbizu/pairwiseAdonis). Comparison 
of abundances at different taxonomic levels was visualized with bar plots using ggplot2 using the 
exported taxonomy tables from QIIME2, and Kruskal-Wallis for significance testing. Differential 
abundance at genus level was performed on physeq object using DESeq2, as implemented within 
microbiomeSeq, with modifications on the differential_abundance and plot_signif scripts to allow 
log2 fold change comparisons between chronically DSS-treated (cDSS) and chronically DSS-treated 
with FMT treatment (cDSS + FMT) groups. Statistical significance of log2 fold changes was assessed 
using the default Wald test with Benjamin-Hochberg p-value correction in DESeq2. Cut-off for all 
significance tests was set at P < 0.05. 
2.11.3. PICRUSt Analysis 
Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) 
was used to predict metagenome function from the 16S rRNA gene data. QIIME2 output was made 
compatible with PICRUSt by performing closed-reference OTU picking with qiime vsearch, using 
Greengenes database (13_8 99% OTUs release). The output feature table was then exported into 
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Biological Observation Matrix (BIOM) format and run through the PICRUSt v1.1.3 workflow to 
normalize the copy number, predict metagenomes, and categorize by function using the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) database for metabolic pathways. The 
biom_to_stamp.py script from the Microbiome Helper [39] repository was used to convert the output 
BIOM file from PICRUSt into Statistical Analysis of metagenomic profiles (STAMP)-compatible spf 
format. Bray–Curtis distances were used to determine the similarity of samples based on 
metagenomic composition. Differences in the taxa and predicted molecular functions were analyzed 
by the linear discriminant analysis (LDA) effect size (LEfSe) with default settings (alpha value for the 
factorial Kruskal–Wallis test among classes = 0.05; threshold on the logarithmic LDA score for 
discriminative features = 1.5). 
3. Results 
Therapeutic FMT reduces signs of inflammation in experimental chronic colitis.  
To evaluate if FMT might exert beneficial effects in a chronic intestinal pathologic condition 
similar to that observed in human IBD patients, experimental intestinal inflammation was induced 
in mice by chronic administration of Dextran Sodium Sulphate (DSS, Figure 1). Mucus and feces 
derived from normobiotic mice were repeatedly transferred into colitic mice by oral gavage 5 days 
after the initiation of each DSS treatment, according to the scheme described in Figure 1A. During the 
course of the treatment the body weight of FMT-treated mice did not differ from that of cDSS- treated 
mice (Figure 1B). The histological score was also similar among colitic FMT-treated and untreated 
mice (Figure 1C). Conversely, at sacrifice FMT-treated mice showed a mild increase in colonic length 
(Figure 1D). Moreover, in accordance to what was observed when FMT was administered during 
acute colitis [19], the normobiotic FMT treatment reduced intestinal inflammation, as indicated by a 
strong decrease in the colonic expression of the pro-inflammatory genes interferon gamma (Ifng), 
tumor necrosis factor (Tnf), interleukins 1β (Il1b), 17 (Il17), and 6 (Il6) (Figure 1E). 
 
Figure 1. Therapeutic faecal microbiota transplantation (FMT) ameliorates Dextran Sodium Sulphate 
(DSS)-induced chronic inflammation. (A) Schematic representation of FMT treatment in the chronic 
DSS (cDSS) colitis model. (B,C) Weight loss (B) and hematoxylin-eosin (H&E) staining ((C), scalebar 
100µm, left) and cumulative histological score ((C), right) of colon specimens obtained from untreated 
(closed triangles), colitic (closed circles), or colitic mice treated with FMT (open circles). (D) Colon 
length of untreated (closed triangles), colitic (closed circles), or colitic mice treated with FMT (open 
circles). (E) Colonic expression levels of Il6, Il17, Ifng, Tnf, and Il1b in untreated (white bars), colitic 
(black bars), and FMT-treated (grey bars) mice. Statistical significance was calculated with unpaired 
two-tailed Mann-Whitney test (two-tailed) and expressed as mean ± SEM. Values of P < 0.05 (*), P < 
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0.01 (**), and P < 0.001 (***) were considered as statistically significant. Outliers were detected with 
Grubb’s test 
The intestinal barrier contributes to gut homeostasis through a well-structured epithelial layer, 
the secretion of antimicrobial peptides (AMPs), and the formation of a multi-layer mucous barrier 
[40]. The architecture of the tight junction protein ZO-1, affected by chronic DSS treatment, was 
restored to normal levels upon normobiotic FMT administration (Figure 2A). In agreement with 
previous results [41], expression of mucin genes, such as Muc1, Muc3, and Muc4, and of antimicrobial 
peptide genes (Camp and S100a8) were downregulated in FMT-treated mice (Figure 2B). 
 
Figure 2. Gut intestinal barrier analysis in cDSS upon FMT. (A) ZO-1 immunofluorescence (IF) and 
quantification of untreated (left panel), cDSS (middle panel), and chronic DSS + faecal microbiota 
transplantation (cDSS+FMT) treated (right) mice colonic mucosa. Scalebar, 10 µm. (B) Camp and 
S100a8 and (C) Muc1, Muc3, Muc4 expression by colonic mucosa of untreated (white bars), cDSS 
treated (black bars), and cDSS+ FMT treated (grey bars) mice. Significance was determined using 
unpaired two-tailed Mann-Whitney test and expressed as mean ± SEM. Outliers were detected with 
Grubb’s test. P < 0.05 (*) were regarded as statistically significant. 
Thus, our results show that therapeutic FMT ameliorates intestinal inflammation in settings that 
more closely resemble human IBD pathology, such as that of experimental chronic colitis.  
3.1. Therapeutic FMT Influences the Activation Status of Colonic T Cell Populations 
Gut-associated immune cell populations critically contribute to initiate and sustain intestinal 
inflammation, both in IBD patients [11] and in experimental models of intestinal inflammation [42]. 
Thus, we asked if therapeutic FMT administration during chronic colitis might induce variations in 
the frequency and phenotype of the colonic immune infiltrate. 
At sacrifice, we observed neither frequency nor absolute numbers variations in Invariant 
Natural Killer T (iNKT) and conventional CD4+ and CD8+ T cells (Figure 3A and Supplementary 
Figure 1) in mice treated or not with FMT. Nonetheless, T cell populations isolated from colons of 
FMT-treated mice showed a reduced proliferative capacity as compared to those isolated from colitic 
mice that had not received the FMT treatment (Figure 3B-D). Phenotypically, mice receiving FMT 
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displayed a lower proportion of CD4+ T and CD8+ T cells expressing the cytotoxicity-associated 
molecule CD107a [43], additionally supporting the observation that colonic T cells in FMT-treated 
mice manifest a reduced pro-inflammatory phenotype. To note, at sacrifice CD69 expression on T 
cells was similar in FMT-treated and untreated mice (Supplementary Figure 2). 
Interestingly, the expansion of the innate lymphocytes ILC2 and ILC3, but not of ILC1, observed 
in the lamina propria of chronically DSS-treated mice, was reduced upon FMT treatment 
(Supplementary Figure 3). 
 
Figure 3. Therapeutic FMT modulates T cell phenotypes. (A) Frequencies and absolute numbers of 
colonic CD4+ T, CD8+ T cells, and Invariant Natural Killer T (iNKT) cells in untreated (white bars), 
chronic-DSS-treated (black bars), and FMT-treated (grey bars) mice 63 days after starting DSS 
administration. (B) Representative dot plots and (C,D) frequencies and absolute numbers of Ki67+ (C) 
and CD107a+ (D) colonic CD4+, CD8+ T cells, and iNKT cells in untreated (white bars), DSS-treated 
(black bars), and FMT-treated (grey bars) mice in the chronic setting. Significance was determined 
using unpaired Mann-Whitney test and expressed as mean ± SEM. P < 0.05 (*), P < 0.01 (**), P < 0.001 
(***) were regarded as statistically significant. Total untreated n = 8, cDSS-treated n = 10, cDSS + FMT 
n = 10 in 2 independent experiments. Outliers were detected with Grubb’s test.  
At sacrifice, similar to what was observed in T cell populations, also the frequency (Figure 4A) 
and the absolute numbers (Figure 4B) of professional antigen-presenting cells (APCs), including 
dendritic cells, macrophages, B cells, and neutrophils, did not substantially differ between FMT-
treated and not-FMT-treated groups. On the contrary, the numbers of colonic MHC-II-expressing 
professional APCs were reduced, albeit not significantly, in FMT-treated mice (Figure 4C), suggesting 
a functional modulation of mucosal APCs’ functions by FMT. 
Taken together, these data indicate a specific effect of therapeutic FMT on the functional status 
of infiltrating innate and adaptive immune cell populations. 
 
Cells 2019, 8, 517 9 of 18 
 
Figure 4. Antigen-presenting cells frequency and phenotype in cDSS-treated mice upon FMT. (A,B) 
Frequency (A) and absolute numbers (B) of colonic dendritic cells (CD45.2+CD3-CD11c+), 
macrophages (CD45.2+CD3-F4/80+), B cells (CD45.2+CD3-CD19+), and neutrophils (CD45.2+CD3-
Ly6g+CD11b+) in cDSS-treated (black bars) and cDSS+FMT-treated (white bars) mice. (C) Absolute 
numbers of MHC-II expression in colonic dendritic cells, macrophages, B cells, neutrophils in cDSS-
treated (black bars), and cDSS + FMT-treated (white bars) mice. 
3.2. Therapeutic FMT Targets the Cytokine Profile of Colonic Immune Cell Populations 
Cytokines produced by mucosal immune cells play a pivotal role in the maintenance of 
homeostasis, as in the initiation and propagation of intestinal inflammation [44]. 
The colonic protein levels of the homeostatic cytokine IL-10 were significantly reduced in colitic 
mice and restored to those of healthy mice upon FMT treatment (Figure 5A). 
Colonic T cells and Lineage (CD11c, CD11b, and CD19) positive leukocytes isolated from 
chronically inflamed colitic mice showed an increase in the secretion of pro-inflammatory cytokines, 
including interferon gamma (IFNγ) and interleukins 17 (IL-17) and 13 (IL-13), which was significantly 
reduced upon FMT treatment (Figure 5B), indicating that the observed amelioration of the 
inflammatory conditions of FMT-treated mice (Figure 1) was associated not only with a reduced 
proliferative capacity (Figure 2) but also with an overall reduced pro-inflammatory potential of 
mucosal immune cells. 
 
Figure 5. FMT reduces immune cell pro-inflammatory cytokine profile. (A) IL10 protein levels in 
colonic tissues of untreated (white bars), cDSS-treated (black bars), and cDSS+ FMT-treated (grey 
bars) mice. (B) IFNγ, IL17 and IL13 production by iNKT cells (left panels), CD4+ T cells (middle 
panels), and Lineage positive cells (CD11c, CD11b, CD19, right panels) in untreated (white boxes), 
cDSS-treated (Black boxes), and cDSS + FMT (Light grey boxes) mice. Significance was determined 
using unpaired Mann-Whitney test and expressed as mean ± SEM. P < 0.05 (*) were regarded as 
statistically significant. Outliers were detected with Grubb’s test. 
3.3. Therapeutic FMT Restores Normobiotic Microbial Ecologies 
Next, to evaluate if the resolution of inflammation in FMT-treated mice was associated with 
changes in the gut microbiota composition, fecal samples of untreated, colitic, and FMT-treated mice 
were analyzed by 16S rRNA sequencing on the Illumina Miseq platform (Figure 6). 
Principal component analysis (PCA) of unweighted UniFrac metric showed separation among 
treatment groups, with a significant difference between cDSS and cDSS + FMT (PERMANOVA, padj 
< 0.05) (Figure 6A; Supplementary Figure 4A–C). 
As previously shown [45], chronic DSS treatment is associated with a decrease in alpha diversity 
upon chronic DSS treatment, particularly in species diversity indices (ANOVA; Simpson, p < 0.05; 
Shannon, p < 0.05) (Supplementary Figure 5). At the end of FMT treatment in chronically colitic mice 
the overall bacterial composition of fecal samples at phylum level was not significantly changed as 
compared to DSS-treated mice (Figure 6B). Consistent with previous reports [46], no change in 
abundance was observed among the most abundant phyla, including Firmicutes and Bacteroidetes 
(Figure 6B). Nonetheless, at lower taxonomic levels, FMT-treated mice showed partial restoration of 
Bifidobacteriaceae and Erysipelotrichaceae families (Figure 6B and Supplementary Figure 6A–B), which 
are immunomodulatory short chain fatty acids (SCFA)-producing taxa, previously shown to be 
associated with healthy gut ecosystems [19]. 
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Differential abundance analysis at genus level showed significant differences between the cDSS 
and cDSS + FMT groups, with increased Parabacteroides and Ruminoclostridium in cDSS mice (Wald 
test, p < 0.01), and increased Lachnospiraceae, Anaeroplasma, Ruminococcaceae UCG-0013, and 
Ruminococcaceae UCG-0014 in cDSS + FMT mice (Wald test, p < 0.05) (Figure 6C). 
Among these differentially abundant taxa, Parabacteroides, Anaeroplasma, and Ruminoclostridium 
ranked as the most important to the microbial community, as measured by mean decrease in 
accuracy, suggesting that FMT treatment has more impact on these taxa in the gut microbiome 
environment in colitic mice (Figure 6D). 
At the species level, FMT-treated mice showed a significant decrease in Parabacteroides goldstenii 
(Figure 6E), as well as a partial decrease in Bacteroides acidifaciens, Escherichia-Shigella, and Blautia 
genera, taxa overrepresented in murine models of intestinal inflammation and in IBD patients [7]. On 
the contrary, Odoribacter spp. and Lactobacillus C30A, two SCFA-producers present at low levels in 
DSS-treated mice [19] and in IBD patients [14], showed a slight increase upon FMT (Figure 6E). 
Next, the microbiota profiles were used for functional prediction using PICRUSt. Among the 
differentially represented functions between the two groups, we observed an increase in tryptophan 
metabolism (an intermediate of the aryl hydrocarbon receptor pathway), impaired in the context of 
intestinal inflammation [47], as well as in metabolism of amino acids associated with bacterial 
fermentation [48] in FMT-treated compared to cDSS mice. 
Several pathways associated with bacterial hyperproliferation (phenylalanine metabolism, 
bisphenol degradation, transcription-related proteins, fatty acid biosynthesis) and inflammatory 
responses were reduced in FMT-treated mice. Among them, the metabolic pathway converting 
linoleic acid into arachidonic acid, which is highly active in UC patients [49], was significantly 
reduced upon FMT (Figure 6F). 
Taken together, these findings suggest that the beneficial effects of FMT during chronic intestinal 
inflammation may originate from the functional reshuffling of the entire microbiota population 
towards anti-inflammatory activities. 
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Figure 6. Gut microbiota analysis upon Faecal Microbiota Transplantation (FMT) in the chronic colitis 
model. (A) Microbiome clustering based on Principal Coordinate Analysis (PCoA) of unweighted 
UniFrac distances of fecal gut microbiota derived from untreated (violet dots), cDSS- (blue dots), and 
cDSS + FMT (yellow dots)-treated mice. Significant differences in beta-diversity between cDSS and 
cDSS + FMT groups were determined by beta-dispersion and Permutational Multivariate analysis of 
variance (PERMANOVA) with p-value correction by Bonferonni (padj), with P < 0.05 as cut-off for 
significance. (B) Bar plots showing taxonomic composition in untreated, cDSS, and DSS + FMT 
groups, including only taxa with relative abundance >1%, at phylum (left panel) and family (right 
panel) level. (C) Log-relative normalised abundances in untreated (violet boxes), cDSS- (blue boxes), 
and cDSS + FMT (yellow boxes)-treated mice of genera found to be differentially abundant in cDSS 
and cDSS + FMT mice, as determined by DESeq2. Log2 fold change (log2FC) relative to cDSS group 
is reported for each genus. Negative log2FC indicates decreased abundance in cDSS compared to 
cDSS + FMT, whereas positive log2FC indicates increased abundance in cDSS compared to cDSS + 
FMT. Significant differences in log2FC were determined by Wald test with p-value correction by 
Benjamin and Hochberg. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***), P < 0.0001 (****) were regarded as 
statistically significant. (D) Ranking of differentially abundant taxa in cDSS and cDSS + FMT mice by 
importance to microbial community, as determined by their Mean Decrease in Accuracy (MDA) using 
a Random Forest classifier. Higher MDA means greater importance. (E) Relative abundances of 
bacterial species in untreated (white bars), cDSS (dark grey bars), and cDSS + FMT (light grey) treated 
mice. (F) Predicted metabolic attributes between cDSS and cDSS + FMT groups. Sequences were used 
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to predict functions against the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, which 
is implemented in Phylogenetic Investigation of Communities by Reconstruction of Unobserved 
States (PICRUSt) software package. 
4. Discussion 
A growing interest is emerging for FMT as a therapy for infectious and chronic diseases 
characterized by microbial alterations. FMT has demonstrated to be highly effective for the treatment 
of antibiotic-resistant recurrent Clostridium Difficile infection (CDI) [23,50] and has shown promising 
results for treatment of Inflammatory Bowel Diseases (IBD), particularly ulcerative colitis (UC) [24–
26]. 
Successful trials involving UC patients demonstrated that restoration of normobiosis correlates 
with clinical remission [24–26]. From a mechanistic point of view, we have recently shown that 
therapeutic FMT treatment in experimental models of acute colitis not only introduced beneficial 
modifications in the dysbiotic microbiota, but also impacted on frequencies and cytokine profiles of 
both innate and adaptive immune cells, as a consequence of an IL10-dependent amelioration of the 
inflammatory status [19]. 
Here we extended these observations to a chronic model of intestinal inflammation, which more 
closely resembles the clinical and immunological features observed in UC patients [11]. One 
important point that emerged from the human UC and CDI trials indicated that induction and 
maintenance of disease remission required multiple FMT administrations [23,50]. Based on these 
observations, to ensure proper engraftment of the healthy microbial communities, we adopted a 
protocol of repeated administration of healthy mucus and feces for 4 days per DSS cycle, and this 
protocol confirmed successful therapeutic outcomes.  
Our results are in agreement with the findings of the patient’s clinical trials, as well as largely 
with our previous observations in the acute experimental models, indicating conserved mechanisms 
linking gut microbiota and immune system functions.  
The successful RCTs in UC patients [24–26] demonstrated that clinical remission correlates with 
stable changes of the gut microbiota composition and metabolism towards functional normobiosis 
restoration [51]. Relevant changes in the levels of Erysipelotrichaceae and Lactobacillaceae have been 
described both in IBD patients and in animal models of intestinal inflammation [3,7,52]. Here we 
found that these taxa were also similarly altered in chronically inflamed mice, and their abundances 
were restored upon therapeutic FMT. Moreover, similarly to the core ecology capable to control 
intestinal inflammation in the acute DSS model [19], also in the chronic setting the presence of 
Lactobacillaceae, Erysipelotrichaceae, Ruminococcaceae, Rikenellaceae, and Lachnospiraceae families 
correlated with resolution of the intestinal inflammation. These taxa share similar metabolic functions 
(i.e, short chain fatty acid production, pH control, free radical scavenging) and are capable of 
controlling the overgrowth of pathogens or pathobionts and to support intestinal homeostasis. These 
metabolic pathways have been shown to be associated with the successful induction of remission in 
UC patients receiving FMT [51]. 
Here, the expansion of these beneficial taxa in FMT-treated mice, and the contraction of pro-
inflammatory taxa, such as Proteobacteria, Enterobacteriaceae, Enterococcaceae, Christensenellaceae, and 
Streptococacceae [7,14], also suggested a shift in the metabolic functions of the microbial ecology. 
Indeed, Phylogenetic Investigation of Communities by Reconstruction of Unobserved States 
(PICRUSt) analyses predicted that the restoration of a normobiotic ecology is associated with 
increased tryptophan (Trp) and isoleucine/leucine metabolism.  
The importance of Trp metabolism in intestinal homeostasis maintenance is underlined by the 
observation that IBD patients manifest low serum levels of Trp [53] and Trp-deficient mice show 
aggravation of colitis and reduced levels of antimicrobial peptides [54]. Re-equilibration of Trp levels, 
for example by dietary intervention, is sufficient to exert anti-inflammatory effects in experimental 
colitis models, to decrease colonic IFNγ and TNF, and to decrease the expression of pro-apoptotic 
factors [55], findings that are congruent with the results we showed here. Moreover, the rate-limiting 
enzyme for Trp metabolism, IDO1, is also expressed by epithelial and antigen presenting cells and 
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its regulation modulates immune responses both locally and systemically. Finally, the gut microbiota 
metabolizes Trp to indole derivatives, which act as ligands for the aryl hydrocarbon receptor (AhR) 
receptor, inducing local production of IL22 and contributing to tissue repair and homeostasis 
maintenance [56], as suggested by the restored barrier functions in FMT-treated mice.  
Interestingly, the increase in leucine and isoleucine metabolism suggests higher nitrogen source 
availability for fermentation, which is one of the key metabolic pathways employed by the enteric 
anaerobic microbiota to produce SCFA. These SCFA-producing fermenting bacteria, in turn, 
stimulate mucus and IgA production, promote tolerance via Treg induction, inhibit nuclear factor κB 
functions, enhance epithelial barrier integrity and repair, and promote competitive exclusion of 
pathogens [57].  
On the other hand, PICRUSt prediction indicates a reduction of the linoleic acid metabolic 
pathway in FMT-treated mice. Linoleic acid, an n-6 polyunsaturated fatty acid, has been implicated 
in inflammatory processes in the gut [49]. It can be metabolized into arachidonic acid, whose 
metabolites, including prostaglandin E2, leukotriene B4, and thromboxane A2, have pro-
inflammatory properties and are increased in the mucosa of patients with ulcerative colitis and in 
animal models of intestinal inflammation [58–60]. The concentrations of linoleic acid and of its 
metabolic products correlate with the degree of histological inflammation and medications currently 
used for IBD patients, such as 5-aminosalicylic acid, inhibit their formation [60]. Hence, the 
restoration of a normobiotic microbial ecology upon FMT treatment is additionally associated with 
changes in functional activities involved in tissue homeostasis. 
The mucosal immune system is pivotal to initiate and sustain intestinal inflammation. T cells, in 
particular, exert pathogenic roles upon the recognition of bacterial antigens [10,61,62]. We [13] and 
others [63,64] reported that IBD patients show increased amounts of pathogenic intestinal Th1, Th17, 
and Th1/17 cells. Moreover, mucosal iNKT cells, a subset of lipid-specific T lymphocytes, can secrete 
pro-inflammatory cytokines in the gut [14] and affect bacterial colonization of the intestine [28,65]. 
Consistently, iNKT cells also perform pathogenic functions towards the intestinal epithelium in 
response to IBD-derived intestinal bacteria [14]. Here we showed that the functional shift in intestinal 
microbial ecology observed upon FMT treatment was sufficient to trigger a reduction in the 
expression of colonic inflammatory genes, such as infg, il1b, and tnf [19,27,66]. 
Furthermore, our data indicate that variations in the gut microbial ecology are capable of 
specifically controlling the proliferative capability of mucosal pathogenic T cell populations and to 
abolish their pro-inflammatory cytokine potential, both for adaptive and innate immune cell 
populations [67]. 
IL-10 is an anti-inflammatory cytokine known for critically contributing to intestinal immune 
homeostasis [68]. During acute colitis, IL-10 secretion by APC and T cells upon FMT was temporally 
linked to the resolution of inflammation [19]. Here, we similarly observed a restoration of IL-10 
mucosal levels, confirming a pivotal function of IL-10 in intestinal homeostasis maintenance [69], also 
in the context of chronic intestinal inflammation.  
Finally, although not statistically significant, FMT treatment reduced the frequency of MHCII+ 
professional antigen-presenting cells in the colonic lamina propria, suggesting that bacterial-antigen 
presentation to CD4+T cells plays an important role in sustaining intestinal immune cell 
pathogenicity, also in the chronic inflammation context. 
5. Conclusions 
Here we demonstrate that the modulation of intestinal microbiota by FMT during chronic 
experimental colitis influences adaptive and innate mucosal immune responses. Normobiosis 
restoration, both in terms of microbial composition and metabolic functions, contributes to 
controlling immune-mediated intestinal inflammation. These findings provide key information to 
elucidate the complex interplay between the immune system and the gut microbial ecosystem during 
chronic inflammatory conditions, especially in light of the increasing implementation of FMT to treat 
diverse human pathologies. 
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